

Table 1. Baseline demographic, clinical, and laboratory data for patients with type 2 diabetes and NAFLD treated with empagliflozin (10 mg/day) or standard treatment (control)

	Empagliflozin	Control	P value
N (M/F)	31 (16/15)	18 (12/6)	0.3771
Age (years)	58.6±12.9	58.6±12.2	0.9867
Body weight (kg)	70.0±19.1	74.4±18.6	0.5035
BMI (kg/m ²)	27.2±5.7	28.4±6.6	0.5258
Waist circumference (cm)	97.6±12.7	100.9±11.5	0.3749
VFA (cm ²)	106.0±49.9	117.3±53.3	0.4794
SBP (mmHg)	134.5±19.5	140.9±21.5	0.3423
DBP (mmHg)	76.9±12.0	75.2±11.0	0.6527
FPG (mg/dl)	173.0±49.4	146.3±33.8	0.0481
HbA1c (%)	8.00±0.86	7.63±0.55	0.1011
LDL cholesterol (mg/dl)	93.3±24.5	100.6±28.2	0.3468
Triglyceride (mg/dl)	122.2±67.9	112.8±57.7	0.6321
HDL-cholesterol (mg/dl)	54.4±16.3	54.2±15.0	0.6863
RLP-cholesterol (mg/dl)	5.1 (2.98, 7.85)	4.35 (2.58, 7.4)	0.5651
AST (U/L)	22.5 (17, 30.5)	25(15.8, 38.5)	0.8071
ALT (U/L)	27.5 (13, 44.8)	22 (14, 34.3)	0.5298
GGT (U/L)	28 (21.8, 55.8)	24 (18.5, 39.5)	0.3545
Uric acid (mg/dl)	5.35±1.30	5.91±1.41	0.1712

Hematocrit (%)	42.7±4.1	40.0±4.8	0.0431
Platelets (×10 ⁹ /mL)	24.3±6.0	24.1±7.2	0.9072
MPV (fl)	10.1±0.6	10.6±1.4	0.0988
eGFR (ml/min/1.73m ²)	77.4±22.0	71.4±25.7	0.3967
PAI-1 (ng/ml)	32.5 (22, 53)	36.5 (18.8, 55)	0.9414
PAP (μg/ml)	0.7 (0.5, 0.8)	0.7 (0.58, 0.95)	0.4277
TAT (ng/ml)	2.0 (1.1, 3.3)	2.9 (1.68, 7.63)	0.0982
HMW adiponectin (μg/ml)	1.66 (0.82, 2.54)	2.75 (1.52, 7.32)	0.0648
Leptin (ng/ml)	12.8 (6.5, 19.4)	12.4 (7.5, 24.1)	0.5868
Metformin/DPP-4i/SU/TZD/Ins, <i>n</i>	15/20/15/5/10	10/13/6/4/5	0.8912
Statin use, <i>n</i> (%)	21 (67.8%)	11 (61.1%)	0.7581
ACEI/ARB/CCB/Diuretics/β-B, <i>n</i>	2/13/9/3/6	1/8/10/2/2	0.7254
Anti-platelet therapy, <i>n</i> (%)	7 (22.6%)	3 (16.7%)	0.7258

Data are the mean±SD or the median and inter-quartile ranges.

BMI, body mass index; VFA, visceral fat area; FPG, fasting plasma glucose; Hb, hemoglobin; ; LDL, low-density lipoprotein; HDL, high-density lipoprotein; RLP, remnant like lipoprotein; AST, aspartate aminotransferase; ALT, alanine transaminase; GGT, γ-glutamyltranspeptidase; eGFR, estimated glomerular filtration; PAI-1, plasminogen activator inhibitor-1; PAP, plasmin-α2-antiplasmin complex ; TAT, thrombin-antithrombin III complex ; HMW, high molecular weight; DPP-4i , dipeptidyl peptidase-4 inhibitors; SU, sulfonylurea; TZD, thiazolidinedine; Ins, insulin; ACEI, angiotensin-converting-enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium channel

blocker.